Robaxisal and Superinfection - a phase IV clinical study of FDA data
Summary:
We study 2,761 people who take Robaxisal (aspirin; methocarbamol) or have Superinfection. No report of Superinfection is found in people who take Robaxisal.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Robaxisal?
Robaxisal has active ingredients of aspirin; methocarbamol. It is often used in back pain. eHealthMe is studying from 223 Robaxisal users. Check the latest studies of Robaxisal.
What is Superinfection?
Superinfection is found to be associated with 311 drugs and 472 conditions by eHealthMe. Check the latest studies of Superinfection.
No report is found.
Do you take Robaxisal and have Superinfection?
- Check whether Superinfection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Robaxisal:
- Robaxisal (223 reports)
Superinfection treatments and more:
- Superinfection (2,538 reports)
How severe was Superinfection and when was it recovered:
Expand to all the drugs that have ingredients of aspirin; methocarbamol:
Browse all side effects of Robaxisal:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Superinfection:
Browse all the conditions that are associated with Superinfection:
How the study uses the data?
The study uses data from the FDA. It is based on aspirin; methocarbamol (the active ingredients of Robaxisal) and Robaxisal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Luvox and Valproic Acid - 3 seconds ago
- Tudorza Pressair vs. Qvar 80, side effect and effectiveness comparison - 3 seconds ago
- Eligard vs. Rapaflo, side effect and effectiveness comparison - 6 seconds ago
- Breast Cancer Metastatic and Night Sweats - 7 seconds ago
- Could Tramadol cause Blood Uric Acid Increased? - 9 seconds ago
- Drug interactions of Androgel and Alcohol - 10 seconds ago
- Could Compazine cause Nosebleed? - 25 seconds ago
- Could Zoledronic cause Hypokalemia? - 25 seconds ago
- Could Darvocet-N 50 cause Heart Attack? - 29 seconds ago
- Drug interactions of Trileptal and Codeine - 31 seconds ago